Pharmaceutical giant Sanofi SA announced a significant contract on Thursday, agreeing to pay up to €320 million ($353 million) for an exclusive license. The recipients are U.S. biotechnology firm RadioMedix Inc. and French medicine developer Orano Med, and the agreement centers on a radiation treatment targeted at rare cancers. This deal underlines the growing synergy between major pharmaceutical companies and biotech innovators aimed at addressing niche medical needs.
For more information, you can read the full article here.